Press Releases

<<  Back

  View printer-friendly version

Aimmune Therapeutics to Present at the 2015 Credit Suisse Healthcare Conference

— Presentation on November 11, 2015, at 2:00 p.m. MT

BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 2, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it will present at the 2015 Credit Suisse Healthcare Investor Conference.

About the Presentation

  • Wednesday, November 11, 2015, at 2:00 p.m. Mountain Time
  • The live audio webcast of the presentation can be accessed from the Investor Relations section of the company’s website at www.aimmune.com.
  • A replay will be available for 14 days following the presentation.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., founded in 2011 as Allergen Research Corporation (ARC), is a clinical-stage biopharmaceutical company developing treatments for peanut allergy and other food allergies. Aimmune Therapeutics’ characterized oral desensitization immunotherapy (CODIT™) system, an approach to oral immunotherapy (OIT), uses rigorously characterized product candidates with gradual, controlled up-dosing protocols to achieve clinically meaningful desensitization to food allergens. Aimmune Therapeutics recently completed a Phase 2 study of its lead product, AR101, a complex mixture of naturally occurring proteins and pharmaceutical-grade ingredients for the treatment of peanut allergy, one of the most common food allergies. For more information, please see www.aimmune.com.

Source: Aimmune Therapeutics, Inc.

Investors
Aimmune Therapeutics, Inc.
Amy Figueroa, 650-352-1039
investorrelations@aimmune.com
or
Media
Edelman
Amanda Breeding, 415-229-7649
amanda.breeding@edelman.com